About astellas pharma inc. - ALPMY
Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. Its products: XTANDI, PADCEV, XOSPATA, VYLOY, VEOZAH, IZERVAY, EVRENZO, BETANIS and PROGRAF. The company was founded by Kenji Yamanouchi in April 1923 and is headquartered in Tokyo, Japan.
ALPMY At a Glance
Astellas Pharma, Inc.
2-5-1 Nihonbashi-Honcho
Tokyo, Tokyo 103-8411
| Phone | 81-3-3244-3000 | Revenue | 14.20B | |
| Industry | Pharmaceuticals: Major | Net Income | 1.93B | |
| Sector | Health Technology | 2026 Sales Growth | 13.172% | |
| Fiscal Year-end | 03 / 2027 | Employees | 14,099 | |
| View SEC Filings |
ALPMY Valuation
| P/E Current | 12.295 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 14.66 |
| Price to Sales Ratio | 2.004 |
| Price to Book Ratio | 2.467 |
| Price to Cash Flow Ratio | 7.57 |
| Enterprise Value to EBITDA | 7.586 |
| Enterprise Value to Sales | 2.178 |
| Total Debt to Enterprise Value | 0.137 |
ALPMY Efficiency
| Revenue/Employee | 1,006,889.41 |
| Income Per Employee | 137,218.273 |
| Receivables Turnover | 2.965 |
| Total Asset Turnover | 0.634 |
ALPMY Liquidity
| Current Ratio | 1.167 |
| Quick Ratio | 0.895 |
| Cash Ratio | 0.231 |
ALPMY Profitability
| Gross Margin | 74.551 |
| Operating Margin | 19.619 |
| Pretax Margin | 17.687 |
| Net Margin | 13.628 |
| Return on Assets | 8.646 |
| Return on Equity | 17.90 |
| Return on Total Capital | 12.304 |
| Return on Invested Capital | 13.548 |
ALPMY Capital Structure
| Total Debt to Total Equity | 36.76 |
| Total Debt to Total Capital | 26.879 |
| Total Debt to Total Assets | 18.849 |
| Long-Term Debt to Equity | 22.35 |
| Long-Term Debt to Total Capital | 16.342 |